Considering that the dysfunction of parvalbumin-positive GABAergic neurons by NMDA receptor antagonists was mediated by oxidative mechanisms (114), some antioxidants might be novel therapeutics or lead compounds to ameliorate the cognitive deficits and histological disease process in schizophrenia patients. This evidence concerns the gene PVALB and schizophrenia.